ProKidney (PROK) Stock Price, News & Analysis

Company Overview

ProKidney, Inc. (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products. These candidates are designed to mitigate inflammatory responses, promote tissue repair and reduce the progression of kidney damage in hospitalized patients at risk of AKI, including those undergoing major surgery or experiencing sepsis. In addition to its clinical-stage portfolio, the company maintains preclinical efforts exploring broader applications in CKD and related nephrology indications.

Founded in 2015 and headquartered in Massachusetts, ProKidney completed its initial public offering in 2022, trading on the NASDAQ under the ticker PROK. The management team comprises professionals with expertise in nephrology research, cell therapy manufacturing and clinical development. ProKidney conducts its clinical trials predominantly in the United States, collaborating with academic medical centers and specialized contract research organizations to advance its pipeline toward regulatory milestones.

Key Stats

• Today's Range: $2.25 to $2.44
• 50-Day Range: $0.57 to $5.18
• 52-Week Range: $0.46 to $7.13
• Volume: 1.40 million shs
• Average Volume: 1.61 million shs
• Market Capitalization: $662.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.25
• Consensus Rating: Hold

ProKidney Stock Analysis - MarketRank™

ProKidney scored higher than 62% of companies evaluated by MarketBeat, and ranked 401st out of 928 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

ProKidney has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 3 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

ProKidney has a consensus price target of $6.25, representing about 177.8% upside from its current price of $2.25.

Amount of Analyst Coverage

ProKidney has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ProKidney are expected to grow in the coming year, from ($0.57) to ($0.33) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ProKidney is -3.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ProKidney is -3.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.75% of the float of ProKidney has been sold short.

Short Interest Ratio / Days to Cover

ProKidney has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ProKidney has recently increased by 14.80%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ProKidney does not currently pay a dividend.

Dividend Growth

ProKidney does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.75% of the float of ProKidney has been sold short.

Short Interest Ratio / Days to Cover

ProKidney has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ProKidney has recently increased by 14.80%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.54

News Sentiment

ProKidney has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for ProKidney this week, compared to 3 articles on an average week.

Search Interest

Only 23 people have searched for PROK on MarketBeat in the last 30 days. This is a decrease of -26% compared to the previous 30 days.

MarketBeat Follows

Only 7 people have added ProKidney to their MarketBeat watchlist in the last 30 days. This is a decrease of -59% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ProKidney insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $312,510.00 in company stock.

Percentage Held by Insiders

41.49% of the stock of ProKidney is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

51.59% of the stock of ProKidney is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PROK Stock Analysis - Frequently Asked Questions

How have PROK shares performed this year?

ProKidney's stock was trading at $1.69 at the start of the year. Since then, PROK stock has increased by 33.1% and is now trading at $2.25.

How were ProKidney's earnings last quarter?

ProKidney Corp. (NASDAQ:PROK) issued its earnings results on Tuesday, August, 12th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. The firm had revenue of $0.22 million for the quarter.

Who are ProKidney's major shareholders?

ProKidney's top institutional investors include JPMorgan Chase & Co. (0.57%), Geode Capital Management LLC (0.35%), Bank of America Corp DE (0.29%) and Jane Street Group LLC (0.20%). Insiders that own company stock include Control Empresarial De Capital, Pablo G Legorreta and Darin J Weber.
View institutional ownership trends.

How do I buy shares of ProKidney?

Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ProKidney own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ProKidney investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Tesla (TSLA).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 9/07/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PROK
• CIK: 1850270
• Web: www.prokidney.com
• Phone: 336-999-7028
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Price Target and Rating

• Average Price Target for ProKidney: $6.25
• High Price Target: $9.00
• Low Price Target: $1.00
• Potential Upside/Downside: +177.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$61.19 million
• Net Margins: N/A
• Pretax Margin: -31,053.89%
• Return on Equity: N/A
• Return on Assets: -17.11%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.48
• Quick Ratio: 11.48

Sales & Book Value

• Annual Sales: $80 thousand
• Price / Sales: 8,276.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.41) per share
• Price / Book: -0.66

Miscellaneous

• Outstanding Shares: 294,280,000
• Free Float: 172,184,000
• Market Cap: $662.13 million
• Optionable: Optionable
• Beta: 1.74